The effect of continuation of anti-platelet agents on bleeding complications after dentoalveolar surgical procedures

Submission date	Recruitment status	Prospectively registered
08/03/2006	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
08/03/2006	Completed	Results
Last Edited	Condition category	Individual participant data
19/08/2009		Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr M.H. Frank

Contact details

Academic Medical Center (AMC)
Department of Oral and Maxillofacial Surgery
P.O. Box 22660
Amsterdam
Netherlands
1100 DD
+31 (0)20 5662300
m.h.frank@amc.uva.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Acronym

BLACK

Study objectives

Common traditional practice until now has been discontinuation of the antiplatelet therapy 7 to 10 days prior to dental surgery, but controlled prospective data in the literature to support this practice are lacking. The discontinuation of antiplatelet treatment to ensure an adequate hemostasis during and after dental surgery needs to be offset against the (rebound) risk of thrombo-embolic complications if this treatment is stopped.

The hypothesis is that antiplatelet therapy can safely be continued prior to dental surgery.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Received from local medical ethics committee

Study design

Randomised double blind placebo controlled parallel group trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Parodontitis apicalis, adult parodontitis, caries

Interventions

Patients will be randomised to continue their medication of anti-platelet agents during the ten days prior to the procedure or to stop treatment. The study will be double blind; hence, patients will receive their initial medication in the form of study medication or placebo in the form of study medication for ten days prior to their treatment.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Peri-procedural blood loss

Secondary outcome measures

- 1. Occurrence of thrombo-embolic events at 30 days follow-up
- 2. The predictive effect of measurements in DNA, blood and saliva on peri-procedural hemostasis and blood loss

Overall study start date

01/09/2005

Completion date

01/09/2007

Eligibility

Key inclusion criteria

- 1. Patient on antiplatelet therapy who has to be treated in the AMC at the Department of Oral and Maxillofacial surgery
- 2. Approval of the prescribing physician
- 3. At least 18 years old

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

145

Key exclusion criteria

- 1. Known coagulation defect
- 2. Use of oral anticoagulant treatment (vitamin K antagonists) or therapeutic heparin
- 3. Severe kidney dysfunction (creatinine clearance <20 ml/min) or hepatic dysfunction
- 4. Unstable coronary artery disease

- 5. Patients younger than 18 years of age
- 6. Refusal to provide informed consent
- 7. Recent placement of a coronary stent (during the last 6 months)

Date of first enrolment

01/09/2005

Date of final enrolment

01/09/2007

Locations

Countries of recruitment

Netherlands

Study participating centre Academic Medical Center (AMC)

Amsterdam Netherlands 1100 DD

Sponsor information

Organisation

Academic Medical Centre (AMC) (Netherlands)

Sponsor details

Department of Oral and Maxillofacial Surgery P.O. Box 22660 Amsterdam Netherlands 1100 DD

Sponsor type

Not defined

ROR

https://ror.org/03t4gr691

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Academic Medical Center (AMC) Department of Oral- and Maxillofacial Surgery and Department of Internal Medicine (Netherlands)

Results and Publications

Publication and dissemination planNot provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration